Press release
Alzheimer's Disease Market Set To Witness Spells of Growth in the 7MM By 2032, DelveInsight
Alzheimer's Disease Market
Alzheimer's disease: An Overview
Alzheimer's disease is a debilitating neurological disorder that progressively mars the memory and cognitive flexibility and functioning of the brain. The patients find it difficult to perform daily routine things such as driving a car, preparing a meal, paying bills, or memorizing things. Alzheimer's disease is the most common cause of dementia, accounting for 60-80% of dementia cases.
Download a sample copy of the report @ https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=ypr
Key highlights of the Alzheimer's disease Market Report
• According to a review article entitled "Alzheimer Disease" by Liana G. Apostolova et al., one nationally representative US data set, the Aging, Demographics, and Memory Study (ADAMS), estimated that in the United States, 14% of people of 71 years and older have dementia. Alzheimer's disease (AD) accounted for 70% of the dementia cases across the age spectrum in this cohort [2016].
• As per Shaheen E Lakhan et. al., according to a 2017 report, AD affects an estimated 6.08 million people in the US, and approximately 200,000 people younger than 65 years with AD constitute the younger-onset US population with AD [2019].
• According to Alzheimer's Association, more women than men have Alzheimer's or other dementias.
Alzheimer's disease Epidemiology Insights
Alzheimer's worsens over time. Alzheimer's is a progressive disease, where dementia symptoms gradually worsen over a number of years. In its early stages, memory loss is mild, but with late-stage Alzheimer's, individuals lose the ability to carry on a conversation and respond to their environment. Alzheimer's is the sixth-leading cause of death in the United States. On average, a person with Alzheimer's lives 4-8 years after diagnosis, but can live as long as 20 years, depending on other factors.
Alzheimer's disease Epidemiology Segmentation in the 7MM
• Total Prevalent Cases
• Age-specific Prevalent Cases
• Gender-specific Prevalent Cases
• Diagnosed and Treatable Cases
Explore more information on the report @ https://www.delveinsight.com/report-store/alzheimers-disease-ad-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=ypr
Alzheimer's disease Market Insights
Alzheimer's disease attacks brain cells and neurotransmitters (chemicals that carry messages between brain cells), affecting the way brain functions, memory and behavior. It is also the most common form of dementia. There is no known cure for disease, and current approaches focus on helping people maintain mental function, manage behavioral symptoms, and slow down certain problems, such as memory loss. Two categories of drugs are approved for the treatment of Alzheimer disease: cholinesterase inhibitors and partial N-methyl D-aspartate (NMDA) antagonists.
Alzheimer's Disease Drugs Types
The U.S. Food and Drug Administration (FDA) has approved two types of medications - cholinesterase inhibitors (Aricept, Exelon, Razadyne) and memantine (Namenda) - to treat the cognitive symptoms (memory loss, confusion, and problems with thinking and reasoning) of Alzheimer's disease.
Alzheimer's disease Treatment Market
Currently, Alzheimer's is at the forefront of biomedical research. Researchers are working to uncover as many aspects of Alzheimer's disease and other dementias as possible. Some of the most remarkable progress has shed light on how Alzheimer's affects the brain. The hope is that better understanding will lead to new treatments. Many potential approaches are currently under investigation worldwide. Researchers hope to develop therapies targeting specific genetic, molecular, and cellular mechanisms so that the actual underlying cause of the disease can be stopped or prevented.
Request a sample copy of the report @ https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=ypr
Alzheimer's Disease Market Dynamics
The dynamics of the Alzheimer's Disease (AD) market is anticipated to change in the coming years owing to the improvement in the rise in number of healthcare spending across the world. Key players, such as Eisai Inc., Anavex Life Sciences Corp., etc. are involved in developing drugs for Alzheimer's Disease (AD).
Alzheimer's Disease Market Companies
• Shanghai Green Valley Pharmaceuticals
• Eisai Inc., and several others
Alzheimer's Disease Market Drugs
• Oligomannate
• BAN2401, and Several Others
Table of Content
1. Key Insights
2. Executive Summary of Alzheimer's Disease
3. Competitive Intelligence Analysis for Alzheimer's Disease
4. Alzheimer's Disease: Market Overview at a Glance
5. Alzheimer's Disease: Disease Background and Overview
6. Patient Journey
7. Alzheimer's Disease Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Alzheimer's Disease Unmet Needs
10. Key Endpoints of Alzheimer's Disease Treatment
11. Alzheimer's Disease Marketed Products
12. Alzheimer's Disease Emerging Therapies
13. Alzheimer's Disease: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Alzheimer's Disease
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Connect with our Business Consultant @ https://www.delveinsight.com/report-store/alzheimers-disease-ad-market?utm_source=SatPR&utm_medium=pressrelease&utm_campaign=ypr
Contact Us
Yash
info@delveinsight.com
About Us
DelveInsight is a Business Consulting Services and Market research company, providing expert business solutions for the life science business development vertical and offering quintessential advisory services in the areas of R&D, Technical Due Diligence Firms, Strategy Formulation, Operations, Competitive Intelligence Pharma, Competitive Landscaping, and Mergers & Acquisitions.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alzheimer's Disease Market Set To Witness Spells of Growth in the 7MM By 2032, DelveInsight here
News-ID: 2677811 • Views: …
More Releases from DelveInsight Business Research
HER2-Negative Breast Cancer Pipeline and Clinical Trial Analysis: 70+ Players, 7 …
DelveInsight's "HER2-Negative Breast Cancer Pipeline Insight" report delivers an extensive analysis of more than 70 companies and 75 pipeline candidates shaping the HER2-negative breast cancer research landscape. The report features detailed profiles of investigational therapies across both clinical and preclinical stages of development. It also evaluates HER2-negative breast cancer treatments based on therapy type, development phase, route of administration, and molecular classification. In addition, the report identifies and reviews inactive…
Marginal Zone Lymphoma Pipeline and Clinical Trial Analysis: 50+ Players, 50+ As …
DelveInsight's "Marginal Zone Lymphoma Pipeline Insight" report delivers an in-depth analysis of more than 50 companies and 50+ investigational drugs shaping the Marginal Zone Lymphoma (MZL) pipeline ecosystem. The report comprehensively outlines Marginal Zone Lymphoma drug profiles, spanning both clinical-stage and non-clinical development programs.
It further evaluates the Marginal Zone Lymphoma therapeutic landscape based on product classification, development phase, route of administration, and molecular category. Additionally, the report identifies and examines…
Non-Muscle Invasive Bladder Cancer Pipeline and Clinical Trial Analysis: 20+ Pla …
DelveInsight's "Non-Muscle Invasive Bladder Cancer Pipeline Insight" report delivers an in-depth analysis of more than 20 companies and over 22 investigational therapies shaping the NMIBC pipeline landscape.
The report features comprehensive profiles of pipeline candidates, spanning both clinical and preclinical stages of development.
It also presents a detailed therapeutic evaluation of NMIBC drugs based on product category, development phase, route of administration, and molecular classification.
In addition, the study sheds light on discontinued…
Myocardial Infarction Market to Evolve Rapidly Over the Next Decade by 2034, Del …
DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast
https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Alzheimer
Alzheimer Therapeutics Market Breakthrough Innovations and Increasing Treatment …
The Alzheimer Therapeutics Market is rapidly evolving as disease-modifying therapies, early-stage diagnostic tools, and biomarker-driven treatment approaches reshape global management of Alzheimer's disease (AD). As one of the most prevalent neurodegenerative conditions, Alzheimer's affects millions of older adults worldwide. With recent regulatory approvals of anti-amyloid monoclonal antibodies, enhanced imaging technology, and increased R&D investment, the market is experiencing unprecedented momentum.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/51928
Key Takeaways
• Disease-modifying…
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
